Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Freenome is a biotechnology company dedicated to developing simple and accurate blood tests for early cancer detection. By leveraging a multiomics platform that combines machine learning with a deep understanding of tumor biology, Freenome aims to empower individuals and their physicians to catch cancer at its most treatable stages. Their approach analyzes a wide array of biological signals, including genomic, proteomic, and other molecular markers, to identify cancer signatures in the bloodstream.
Serves as the central hub for research and development, corporate operations, data science, and strategic planning for Freenome's early cancer detection technologies.
State-of-the-art laboratory facilities, advanced data analysis infrastructure, and collaborative workspaces designed to foster innovation in diagnostics.
A mission-driven, innovative, and collaborative environment. Employees are typically focused on scientific rigor, patient impact, and working at the cutting edge of biotechnology and machine learning.
Its location in the Bay Area provides access to a rich talent pool, leading research institutions, and a vibrant venture capital ecosystem, crucial for a high-growth biotech company.
Freenome's operations are primarily centered in the United States, with its headquarters and key research facilities located in California. While direct office presence is US-based, its clinical trials may involve sites across North America and potentially other regions. The company's global impact is anticipated through the future commercialization and adoption of its cancer screening tests worldwide, and through collaborations with international research institutions and healthcare organizations.
279 E Grand Ave
South San Francisco
CA
USA
Address: 3560 Dunhill St, San Diego, CA 92121, USA
Expands Freenome's research capabilities by tapping into San Diego's strong biotechnology cluster, including its specialized talent pool and research infrastructure, to accelerate diagnostic innovation.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Freenome' leadership includes:
Freenome has been backed by several prominent investors over the years, including:
Freenome significantly bolstered its executive leadership team over the past 12-18 months with key strategic appointments, including a new Chief Medical Officer, Chief Financial Officer, and Chief Commercial Officer. These hires are aimed at guiding the company through critical phases of product development, clinical validation, and commercialization strategy. No major executive departures have been publicly announced during this period.
Discover the tools Freenome uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Freenome commonly uses the email format combining the first initial and last name. Other potential formats might exist but this is a widely observed pattern for companies of similar structure and industry.
[first_initial][last]@freenome.com
Format
jdoe@freenome.com
Example
85%
Success rate
Freenome Press Release • January 24, 2024
Freenome announced the presentation of new data on its investigational blood-based test for colorectal cancer and advanced adenomas at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The data highlighted the test's performance and potential clinical utility....more
Freenome Press Release • December 5, 2023
Freenome secured $254 million in new financing from new and existing investors. The funds will be used to advance its pipeline of blood-based tests for early cancer detection, including its colorectal cancer screening test, and to expand its multiomics platform....more
Freenome Press Release • August 2, 2023
Freenome announced the appointment of William Quirk as its Chief Financial Officer. Quirk brings over two decades of financial leadership experience in the life sciences industry to Freenome....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Freenome, are just a search away.